The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden

References

• Al Dayel F. EGFR mutation testing in non-small cell lung cancer (NSCLC). J Infect Public Health. 2012;5(Suppl 1):S31–S34.
   PubMedGoogle Scholar
• Dolesova L, Konecny M, Markus J, et al. Molecular analysis of EGFR gene in different types of tumor material from NSCLC patients. Neoplasma. 2015;62(3):439–448.
   PubMed Web of Science ®Google Scholar
• Gelatti ACZ, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer. 2019;137:113–122.
   PubMed Web of Science ®Google Scholar
• Aguiar F, Fernandes G, Queiroga H, et al. Overall survival analysis and characterization of an EGFR mutated non-small cell lung cancer (NSCLC) population. Arch Bronconeumol. 2018;54(1):10–17.
   PubMed Web of Science ®Google Scholar
• Hsu WH, Yang JC, Mok TS, et al. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018;29(Suppl 1):i3–i9.
   PubMed Web of Science ®Google Scholar
• Ghafoor Q, Baijal S, Taniere P, et al. Epidermal Growth Factor Receptor (EGFR) kinase inhibitors and non-small cell lung cancer (NSCLC) - advances in molecular diagnostic techniques to facilitate targeted therapy. Pathol Oncol Res. 2018;24(4):723–731.
   PubMed Web of Science ®Google Scholar
• Brugger W, Thomas M. EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment. Lung Cancer. 2012;77(1):2–8.
   PubMed Web of Science ®Google Scholar
• Deng Q, Xie B, Wu L, et al. Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients. Heliyon. 2018;4(12):e01031.
   PubMed Web of Science ®Google Scholar
• Elamin YY, Gomez DR, Antonoff MB, et al. Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2019;20(1):43–47.
   PubMed Web of Science ®Google Scholar
• Gaut D, Sim MS, Yue Y, et al. Clinical implications of the T790M mutation in disease characteristics and treatment response in patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2018;19(1):e19–e28.
   PubMed Web of Science ®Google Scholar
• Lovly CM, Horn L. Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC. Curr Treat Options Oncol. 2012;13(4):516–526.
   PubMed Web of Science ®Google Scholar
• Maione P, Sacco PC, Casaluce F, et al. Overcoming resistance to EGFR inhibitors in NSCLC. Rev Recent Clin Trials. 2016;11(2):99–105.
   PubMed Web of Science ®Google Scholar
• ESMO. Clinical practice living guidelines – metastatic non-small-cell lung cancer; 2019 [cited 2020 Jun 2]. Available from: https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer
   Google Scholar
• European Medicines Agency (EMA). Vizimpro (dacomitinib) summary of product characteristics; 2019 [cited 2020 Aug 4]. Available from: https://www.ema.europa.eu/en/documents/product-information/vizimpro-epar-product-information_en.pdf.
   Google Scholar
• Food and Drug Administration (FDA). VIZIMPRO (dacomitinib) Prescribing Information; 2018 [cited 2020 Aug 04]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf.
   Google Scholar
• Tandvårds- och läkemedelsförmånsverket. Vizimpro ingår i högkostnadsskyddet; 2019 [cited 2019 Jul 24]. Available from: https://www.tlv.se/beslut/beslut-lakemedel/generell-subvention/arkiv/2019-06-14-vizimpro-ingar-i-hogkostnadsskyddet.html.
   Google Scholar
• Regionala Cancercentrum. Lungcancer Nationellt vårdprogram; 2020 [cited 2020 Jul 28]. Available from: https://www.cancercentrum.se/globalassets/cancerdiagnoser/lunga-och-lungsack/vardprogram/nationellt-vardprogram-lungcancer.pdf.
   Google Scholar
• Bria E, Milella M, Cuppone F, et al. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann Oncol. 2011;22(10):2277–2285.
   PubMed Web of Science ®Google Scholar
• Arriola E, Garcia Gomez R, Diz P, et al. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC Cancer. 2018;18(1):106.
   PubMed Web of Science ®Google Scholar
• Hochmair MJ, Morabito A, Hao D, et al. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncol. 2019;15(25):2905–2914.
   PubMed Web of Science ®Google Scholar
• Regionala Cancercentrum I Samverkan. Regionala Cancercentrum i samverkan. Lungcancer nationell kvalitetsrapport för 2018; 2019 [cited 2020 Jun 28]. Available from: https://www.cancercentrum.se/globalassets/cancerdiagnoser/lunga-och-lungsack/kvalitetsregister/rapport/20191015_nlcr_nationell_rapport_2018.pdf.
   Google Scholar
• Cancerfonden. Cancerfondsrapporten 2018; 2018 [cited 2020 Jul 28]. Available from: https://static-files.cancerfonden.se/Cancerfondsrapporten2018_webb_(2)_1521607903.pdf.
   Google Scholar
• Bergqvist M, Christensen HN, Wiklund F, et al. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010–2016 in Sweden: a nationwide observational study. Int J Cancer. 2019;149(9):2510–2517.
   Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices-overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value Health. 2012;15(6):796–803.
   PubMed Web of Science ®Google Scholar
• Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. Report by the decision support unit June 2011; 2013 [cited 2020 Jul 24]. Available from: http://nicedsu.org.uk/wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf.
   Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50.
   PubMed Web of Science ®Google Scholar
• Mok T, Cheng Y, Zhou X, et al. Updated overall survival from extended follow up in ARCHER 1050: a randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients with EGFR mutation. Annal Oncol. 2019;30:ix200–ix201.
   Web of Science ®Google Scholar
• Pharmaceutical Benefits Board. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2); 2003 [cited 2020 Jul 28]. Available from: https://www.tlv.se/download/18.2e53241415e842ce95514e9/1510316396792/Guidelines-for-economic-evaluations-LFNAR-2003-2.pdf.
   Google Scholar
• Farris M, Larkin-Kaiser K, Scory T, et al. Network meta-analysis of first-line therapy for advanced EGFR mutation positive non-small cell lung cancer: updated overall survival. Future Oncol. 2020;16(36):3107–3116.
   PubMed Web of Science ®Google Scholar
• Franek J, Cappelleri JC, Larkin-Kaiser KA, et al. Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer. Future Oncol. 2019;15(24):2857–2871.
   PubMed Web of Science ®Google Scholar
• Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454–1466.
   PubMed Web of Science ®Google Scholar
• Centre for Reviews and Dissemination, University of York. Systematic reviews: CRD’s guidance for undertaking reviews in health care; 2009 [cited 2020 Jul 24]. Available from: https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf.
   Google Scholar
• Ades AE, Caldwell DM, Reken S, et al. NICE decision support unit technical support documents. Evidence synthesis of treatment efficacy in decision making: a reviewer's checklist. London: National Institute for Health and Care Excellence (NICE); 2012.
   Google Scholar
• Phillippo D. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE; 2016 [cited 2021 Jan]. Available from: https://research-information.bris.ac.uk/ws/portalfiles/portal/94868463/Population_adjustment_TSD_FINAL.pdf.
   Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011;14(4):417–428.
   PubMed Web of Science ®Google Scholar
• Dias S, Ades AE, Welton NJ, et al. Network meta-analysis for decision-making. Hoboken (NJ): Wiley; 2018.
   Google Scholar
• Plummer M. rjags: Bayesian Graphical Models using MCMC. R package version. 4-10; 2019. Available from: https://cran.r-project.org/web/packages/rjags/rjags.pdf
   Google Scholar
• Spiegelhalter D, Thomas A, Best N, et al. BUGS 0.5: Bayesian inference using gibbs sampling–manual (version ii). UK: MRC Biostatistics Unit; 1996.
   Google Scholar
• Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1998;7(4):434–455.
   Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. NICE decision support unit technical support documents. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London: National Institute for Health and Care Excellence (NICE); 2014.
   Google Scholar
• Park K, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–589.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017;28(2):270–277.
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125.
   PubMed Web of Science ®Google Scholar
• Popat S, Mok T, Yang JC, et al. Afatinib in the treatment of EGFR mutation-positive NSCLC-a network meta-analysis. Lung Cancer. 2014;85(2):230–238.
   PubMed Web of Science ®Google Scholar
• Batson S, Mitchell SA, Windisch R, et al. Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. Onco Targets Ther. 2017;10:2473–2482.
   PubMed Web of Science ®Google Scholar
• Li XY, Lin JZ, Yu SH. Front-line therapy in advanced non-small cell lung cancer with sensitive epidermal growth factor receptor mutations: a network meta-analysis. Clin Ther. 2020;42(2):338.e4–350.e4.
   Web of Science ®Google Scholar
• Lin JZ, Ma SK, Wu SX, et al. A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: should osimertinib be the first-line treatment? Medicine (Baltimore). 2018;97(30):e11569.
   PubMed Web of Science ®Google Scholar
• Holleman MS, van Tinteren H, Groen HJ, et al. First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. Onco Targets Ther. 2019;12:1413–1421.
   PubMed Web of Science ®Google Scholar
• Cabanero M, Sangha R, Sheffield BS, et al. Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective. Curr Oncol. 2017;24(2):111–119.
   PubMed Web of Science ®Google Scholar
• Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Wu YL, Schuler M, et al., editors. Subsequent therapies post-afatinib among patients with EGFR mutation-positive NSCLC in LUX-Lung (LL) 3, 6 and 7. Proceedings of the European Society For Medical Oncology (ESMO) Congress; 2017; Madrid, Spain, September 8–12.
   Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Wu Y, Schuler M, et al. PS02.20 subsequent therapies post-afatinib among patients with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung 3, 6 and 7: topic: medical oncology. J Thorac Oncol. 2017;12(11):S1572.
   Web of Science ®Google Scholar
• Burström K, Sun S, Gerdtham U-G, et al. Swedish experience-based value sets for EQ-5D health states. Qual Life Res. 2014;23(2):431–442.
   PubMed Web of Science ®Google Scholar
• AstraZeneca Pharmaceuticals LP. TAGRISSO (osimertinib) tablets, for oral use. Wilmington, DE; 2020. [cited 2021 Apr 6] Available from: https://www.azpicentral.com/tagrisso/tagrisso.pdf#page=1
   Google Scholar
• Chouaid C, Agulnik J, Goker E, et al. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. J Thorac Oncol. 2013;8(8):997–1003.
   PubMed Web of Science ®Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6(1):84.
   PubMed Web of Science ®Google Scholar
• Tandvårds- och läkemedelsförmånsverket. Medicines and consumables database; 2020 [cited 2020 Aug 4]. Available from: https://www.tlv.se/beslut/sok-i-databasen.html.
   Google Scholar
• Sveriges Kommuner och Landsting. Kostnad per patient, KPP; 2018 [cited 2020 Jul 24]. Available from: https://skl.se/ekonomijuridikstatistik/statistik/kostnadperpatientkpp/kppdatabas.1079.html.
   Google Scholar
• Sodraregionsvardsnamnden. Regionala priser och ersättningar för Södra sjukvårdsregionen; 2018 [cited 2020 Jul 28]. Available from: https://sodrasjukvardsregionen.se/avtal-priser/regionala-priser-och-ersattningar/.
   Google Scholar
• Vardgivare Skane. Bild- och funktionsmedicin prislista; 2018 [cited 2020 Jul 24]. Available from: https://vardgivare.skane.se/patientadministration/avgifter-och-prislistor/prislistor-bild-funktionsmedicin/.
   Google Scholar
• Statistikmyndigheten SCB. Average monthly salary, SEK by sector, occupation (SSYK 2012. sex, level of education and year 2018 [cited 2020 Jul 28]. Available from: http://www.statistikdatabasen.scb.se/pxweb/en/ssd/START__AM__AM0110/.
   Google Scholar
• Ekonomifakta. Arbetsmarknad; 2017 [cited 2020 Jul 24]. Available from: https://www.ekonomifakta.se/Fakta/Arbetsmarknad/.
   Google Scholar
• Svensson M, Nilsson FOL, Arnberg K. Reimbursement decisions for pharmaceuticals in Sweden: the impact of disease severity and cost effectiveness. Pharmacoeconomics. 2015;33(11):1229–1236.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer; 2019 [cited 2020 Jul 24]. Available from: https://www.nice.org.uk/guidance/ta595/documents/final-appraisal-determination-document.
   Google Scholar
• Scottish Medicines Consortium. dacomitinib 15mg, 30mg and 45mg film-coated tablets (Vizimpro); 2019 [cited 2020 Jul 24]. Available from: https://www.scottishmedicines.org.uk/media/4706/dacomitinib-vizimpro-final-august-2019-for-website.pdf.
   Google Scholar
• Yu Y, Luan L, Zhu F, et al. PCN164 cost-effectiveness of dacomitinib vs. gefitinib as first-line treatment for egfr mutation positive advanced non-small-cell lung cancer in China. Value Health. 2019;22:S467–S468.
   PubMed Web of Science ®Google Scholar
• Silva ML, Paquete AT, Alarcão J, et al. Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR)-activating mutations in Portugal. Value Health. 2020;23(S2):S447.
   Google Scholar
• Aguiar PN, Jr., Haaland B, Park W, et al. Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer. JAMA Oncol. 2018;4(8):1080–1084.
   PubMed Web of Science ®Google Scholar
• Aguilar-Serra J, Gimeno-Ballester V, Pastor-Clerigues A, et al. Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis. J Comp Eff Res. 2019;8(11):853–863.
   PubMed Web of Science ®Google Scholar
• Bertranou E, Bodnar C, Dansk V, et al. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer. J Med Econ. 2018;21(2):113–121.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer; 2016 [cited 2020 Dec 7]. Available from: https://www.nice.org.uk/guidance/ta653.
   Google Scholar
• National Institute for Health and Care Excellence. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer: Technology appraisal guidance; 2020 [cited 2020 Jan 22; 2020 Aug 4]. Available from: https://www.nice.org.uk/guidance/ta621/resources/osimertinib-for-untreated-egfr-mutationpositive-nonsmallcell-lung-cancer-pdf-82609012217797.
   Google Scholar
• Holleman MS, Al MJ, Zaim R, et al. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. Eur J Health Econ. 2020;21(1):153–164.
   PubMed Web of Science ®Google Scholar
• Cai H, Zhang L, Li N, et al. Cost-effectiveness of osimertinib as first-line treatment and sequential therapy for EGFR mutation-positive non-small cell lung cancer in China. Clin Ther. 2019;41(2):280–290.
   PubMed Web of Science ®Google Scholar
• Wu B, Gu X, Zhang Q. Cost-effectiveness of osimertinib for EGFR mutation-positive non-small cell lung cancer after progression following first-line EGFR TKI therapy. J Thorac Oncol. 2018;13(2):184–193.
   PubMed Web of Science ®Google Scholar
• Wu B, Gu X, Zhang Q, et al. Cost-effectiveness of osimertinib in treating newly diagnosed, advanced EGFR-mutation-positive non-small cell lung cancer. Oncologist. 2019;24(3):349–357.
   PubMed Web of Science ®Google Scholar
• Chouaid C, Luciani L, LeLay K, et al. Cost-effectiveness analysis of afatinib versus gefitinib for first-line treatment of advanced EGFR-mutated advanced non-small cell lung cancers. J Thorac Oncol. 2017;12(10):1496–1502.
   PubMed Web of Science ®Google Scholar
• Wang H, Zeng C, Li X, et al. Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer. Future Oncol. 2019;15(2):181–191.
   PubMed Web of Science ®Google Scholar
• Gu X, Zhang Q, Chu YB, et al. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lung Cancer. 2019;127:84–89.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092.
   PubMed Web of Science ®Google Scholar
• Ting J, Tien Ho P, Xiang P, et al. Cost-effectiveness and value of information of erlotinib, afatinib, and cisplatin-pemetrexed for first-line treatment of advanced EGFR mutation-positive non-small-cell lung cancer in the United States. Value Health. 2015;18(6):774–782.
   PubMed Web of Science ®Google Scholar
• Vergnenegre A, Massuti B, de Marinis F, et al. Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC. J Thorac Oncol. 2016;11(6):801–807.
   PubMed Web of Science ®Google Scholar
• Kimura M, Yasue F, Usami E, et al. Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Mol Clin Onc. 2018;9(2):201–206.
   PubMed Web of Science ®Google Scholar